Cambridge Cognition Holdings PLC
LSE:COG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cambridge Cognition Holdings PLC
Research & Development
Cambridge Cognition Holdings PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Research & Development
-£2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Renalytix PLC
LSE:RENX
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Feedback PLC
LSE:FDBK
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Research & Development
-£3.7m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
P
|
Physitrack PLC
STO:PTRK
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cambridge Cognition Holdings PLC
Glance View
Cambridge Cognition Holdings Plc is a neuroscience digital health company, which engages in the development of digital health products to better understand, detect, and treat conditions affecting brain health. The firm develops and markets digital solutions to assess brain health for sale worldwide, principally in the United Kingdom, the United States and Europe. Its products include CANTAB Recruit, CANTAB Connect, Cognition Kit, Cognition eCOA, CANTAB Connect Research, CANTAB Mobile, CANTAB BrainHealth, CANTAB Insight and NeuroVocalix. Its services include neuroscience consultancy, study design, data analysis, study management, data management plan, reporting and interpretation and technical consultancy. Its CANTAB Connect offers digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas. Its Cognition Kit is a custom-designed digital health platform delivering wearable and smartphone applications for high frequency data collection to demonstrate treatment efficacy and increase the understanding of a disease and a patient's response to medication.
See Also
What is Cambridge Cognition Holdings PLC's Research & Development?
Research & Development
-2.2m
GBP
Based on the financial report for Jun 30, 2025, Cambridge Cognition Holdings PLC's Research & Development amounts to -2.2m GBP.
What is Cambridge Cognition Holdings PLC's Research & Development growth rate?
Research & Development CAGR 1Y
57%
Over the last year, the Research & Development growth was 57%.
